Sy Mukherjee

Sy Mukherjee is a former health care reporter for Fortune.

Page 21 of 100

  • Antibiotics AINewsletters

    How A.I. helps sniff out new antibiotics

    By
  • AUSTRALIA-HEALTH-HOSPITAL-DISEASE-SUPERBUGHealth

    Scientists are turning to A.I. to discover new antibiotics that can fight superbugs

    By
  • Sanofi CEO Paul HudsonNewsletters

    Coronavirus interruption of drug supply chain pushes Sanofi to open a firm in France

    By
  • 2nd China International Import Expo (CIIE) - Day 2Health

    Sanofi is set to launch a new European drug manufacturing firm

    By
  • China coronavirus vaccine smoking menNewsletters

    Smoking, coronavirus, and the deaths of Chinese men

    By
  • A man lowers his face mask to smoke a cigarette in Beijing on Feb. 17, 2020.Health

    China’s high smoking rate may be exacerbating the coronavirus outbreak

    By
  • Coronavirus vaccine SARS lessonsHealth

    SARS treatments could help with the new coronavirus. Why were they shelved?

    By
  • WWI Helmet Study DukeNewsletters

    When innovation doesn’t equal improvement

    By
  • AstraZeneca coronavirusHealth

    AstraZeneca stock slips on mixed earnings report and coronavirus uncertainty

    By
  • Ro Digital Health ClinicNewsletters

    Telehealth startup Ro launches a ‘digital health clinic for men’

    By
  • A new study finds that virtual reality therapy could cut help alleviate pain related with childbirth.Newsletters

    How virtual reality could help women during childbirth

    By
  • Medical debt impacts millions of Americans, and it’s an important issue when discussing changes to the health care system.Newsletters

    What health insurance doesn’t cover

    By
  • Kaiser Permanente Earnings Bernard TysonNewsletters

    Kaiser’s 2019 growth should help expand former CEO Bernard Tyson’s legacy of investing in communities

    By
  • Coronavirus mask medical supply chainNewsletters

    How coronavirus panic is making virus containment more difficult

    By
  • CRISPR Gene Editing Trial Cancer SafetyNewsletters

    First step in study shows CRISPR gene-edited cells are safe for use in cancer patients

    By